Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 16/20 | 0.64 |
| ▸ | CA2 | P00918 | 16/20 | 0.64 |
| ▸ | CA9 | Q16790 | 11/20 | 0.64 |
| ▸ | CA12 | O43570 | 10/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2433442 | 0.98 | CA1 (0.62) | CA1CA2CA9CA12MAPT | |
| SCHEMBL13373495 | 0.85 | CA1 (0.62) | CA1CA2CA9CA12MAPT | |
| SCHEMBL1592707 | 0.85 | LMNA (0.53) | CA1CA2CA9CA12MAPT | |
| SCHEMBL359383 | 0.84 | CA1 (0.73) | CA1CA2CA9CA12MAPT | |
| SCHEMBL4522845 | 0.83 | CA1 (0.64) | CA1CA2CA9CA12MAPT | |
| SCHEMBL361047 | 0.83 | CA1 (0.64) | CA1CA2CA9CA12MAPT | |
| SCHEMBL4151992 | 0.82 | LMNA (0.52) | CA1CA2CA9CA12MAPT | |
| SCHEMBL27747721 | 0.81 | CA1 (0.76) | CA1CA2CA9CA12MAPT | |
| SCHEMBL7495027 | 0.79 | CA1 (0.69) | CA1CA2CA9CA12MAPT | |
| Nitric Acid SCHEMBL2075198 | 0.79 | LMNA (0.48) | CA1CA2CA9CA12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844657-B1 | THERAPEUTIC COMPOUNDS | CHANGZHOU LE SUN PHARMACEUTICALS LTD (CN) | 2017-04-12 | — | — | EP | disclosed |
| US-9062039-B2 | Therapeutic compounds | CHANGZHOU LE SUN PHARMACEUTICALS LIMITED (CN) | 2015-06-23 | — | — | US | disclosed |
| US-20150105413-A1 | THERAPEUTIC COMPOUNDS | CHANGZHOU LE SUN PHARMACEUTICALS LIMITED (CN) | 2015-04-16 | — | — | US | disclosed |
| EP-2844657-A1 | THERAPEUTIC COMPOUNDS | Changzhou Le Sun Pharmaceuticals Limited (CN) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013156780-A1 | THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-10-24 | — | — | WO | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1692140-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
| US-20050228005-A1 | Protein kinase inhibitors and uses thereof | MOON YOUNG C | 2005-10-13 | — | — | US | disclosed |
| US-20050148603-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-07-07 | — | — | US | disclosed |
| WO-2005037843-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| US-6825190-B2 | 4-(1,2- OR 2,1-BENZOXAZOL-5-YL)-2-AMINOPYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-11-30 | — | — | US | disclosed |
| WO-2002102800-A9 | 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2004-05-06 | — | — | WO | disclosed |
| EP-1399440-A1 | 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20040009996-A1 | Protein kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-01-15 | — | — | US | disclosed |
| WO-2002102800-A1 | 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148603-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, MAP3K1, MAP3K6 | CA1 4066/4885CA2 2721/4885CA9 3918/4885 |
| US-20150105413-A1 | THERAPEUTIC COMPOUNDS | CDK9, CDK19, CDK2 | CA1 2543/4885CA2 768/4885CA9 230/4885 |
| US-20040009996-A1 | Protein kinase inhibitors and uses thereof | GSK3A, GSK3B, JAK3 | CA1 4105/4885CA2 2908/4885CA9 2912/4885 |
| US-20050228005-A1 | Protein kinase inhibitors and uses thereof | GSK3A, JAK3, GSK3B | CA1 4022/4885CA2 2981/4885CA9 2991/4885 |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CA1 4066/4885CA2 2721/4885CA9 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.